<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03289962</url>
  </required_header>
  <id_info>
    <org_study_id>GO39733</org_study_id>
    <secondary_id>2017-001475-23</secondary_id>
    <nct_id>NCT03289962</nct_id>
  </id_info>
  <brief_title>A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors</brief_title>
  <official_title>A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biontech RNA Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to
      evaluate the safety, tolerability, immune response, and pharmacokinetics of RO7198457 as a
      single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed
      death-ligand 1 [anti-PD-L1] antibody).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Anticipated">October 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 11, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Phase 1a: Days 1 to 14 / Phase 1b: Days 1 to 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD/Recommended Phase 2 Dose (RP2D) of RO7198457</measure>
    <time_frame>Phase 1a: Days 1 to 14 / Phase 1b: Days 1 to 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs) by Severity According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0</measure>
    <time_frame>Baseline up to end of the study (up to approximately 3 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Immune-Mediated Adverse Events (imAEs) by Severity According to NCI CTCAE Version 4.0</measure>
    <time_frame>Baseline up to end of the study (up to approximately 3 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants by Number of Treatment Cycles Received</measure>
    <time_frame>Baseline up to end of the study (up to approximately 3 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Intensity of RO7198457</measure>
    <time_frame>Baseline up to end of the study (up to approximately 3 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of (R)-N,N,N-Trimethyl-2,3-Dioleyloxy-1-Propanaminium Chloride (DOTMA)</measure>
    <time_frame>Pre-infusion (0 hour [hr]) until treatment discontinuation (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Ribonucleic Acid (RNA)</measure>
    <time_frame>Pre-infusion (0 hr) until treatment discontinuation (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Atezolizumab</measure>
    <time_frame>Pre-infusion (0 hr) until 2 months post treatment discontinuation (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Induction of Antigen-Specific T-Cell Responses in Peripheral Blood</measure>
    <time_frame>Pre-infusion (0 hr) until treatment discontinuation (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune-Related Cytokine Levels</measure>
    <time_frame>Pre-infusion (0 hr) until treatment discontinuation (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST v1.1)</measure>
    <time_frame>Baseline until 90 days after last dose or initiation of another systemic anti-cancer therapy, whichever occurs first (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) According to RECIST v1.1</measure>
    <time_frame>From first occurrence of a documented objective response (CR or PR) until disease progression or death due to any cause, whichever occurs first (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Objective Response of CR or PR According to Immune-Modified RECIST</measure>
    <time_frame>Baseline until 90 days after last dose or initiation of another systemic anti-cancer therapy, whichever occurs first (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR According to Immune-Modified RECIST</measure>
    <time_frame>From first occurrence of a documented objective response (CR or PR) until disease progression or death due to any cause, whichever occurs first (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) According to RECIST v1.1</measure>
    <time_frame>Baseline until 90 days after last dose or initiation of another systemic anti-cancer therapy, whichever occurs first (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline until 90 days after last dose or initiation of another systemic anti-cancer therapy, whichever occurs first (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-Drug Antibodies (ADAs) to Atezolizumab</measure>
    <time_frame>Pre-infusion (0 hr) until 2 months post treatment discontinuation (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">567</enrollment>
  <condition>Melanoma</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Bladder Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Renal Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Other Solid Cancers</condition>
  <arm_group>
    <arm_group_label>Phase 1a Dose-Escalation: RO7198457</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7198457 at escalated dosages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Dose-Escalation: RO7198457 + Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7198457 at escalated dosages along with atezolizumab at a fixed dose of 1200 milligrams (mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Exploration: RO7198457 + Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-small cell lung cancer (NSCLC) cancer immunotherapy (CIT)-treated participants will receive RO7198457 (at dosage lower than maximum tolerated dose [MTD] based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Expansion: RO7198457 + Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with different indications as per inclusion criteria, will receive RO7198457 (at multiple dose levels below MTD based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Expansion: RO7198457 + Atezolizumab (Serial Biopsy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with selected tumor types who consent to optional serial biopsies will receive RO7198457 (at multiple dose levels below MTD based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7198457</intervention_name>
    <description>RO7198457 will be administered by intravenous (IV) infusion, in 21-day cycles.</description>
    <arm_group_label>Phase 1a Dose-Escalation: RO7198457</arm_group_label>
    <arm_group_label>Phase 1b Dose-Escalation: RO7198457 + Atezolizumab</arm_group_label>
    <arm_group_label>Phase 1b Exploration: RO7198457 + Atezolizumab</arm_group_label>
    <arm_group_label>Phase 1b Expansion: RO7198457 + Atezolizumab</arm_group_label>
    <arm_group_label>Phase 1b Expansion: RO7198457 + Atezolizumab (Serial Biopsy)</arm_group_label>
    <other_name>PCV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered by IV infusion, in 21-day cycles.</description>
    <arm_group_label>Phase 1b Dose-Escalation: RO7198457 + Atezolizumab</arm_group_label>
    <arm_group_label>Phase 1b Exploration: RO7198457 + Atezolizumab</arm_group_label>
    <arm_group_label>Phase 1b Expansion: RO7198457 + Atezolizumab</arm_group_label>
    <arm_group_label>Phase 1b Expansion: RO7198457 + Atezolizumab (Serial Biopsy)</arm_group_label>
    <other_name>Tecentriq</other_name>
    <other_name>RO5541267</other_name>
    <other_name>MPDL3280A</other_name>
    <other_name>An engineered anti-PDL1 antibody</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Life expectancy greater than or equal to (&gt;=12 weeks)

          -  Adequate hematologic and end-organ function

          -  Measured or calculated creatinine clearance &gt;=50 milliliters per minute (mL/min) on
             the basis of the Cockcroft-Gault glomerular filtration rate estimation

        Cancer-Specific Inclusion Criteria:

          -  Participants with histologic documentation of locally advanced, recurrent, or
             metastatic incurable malignancy that has progressed after at least one available
             standard therapy; or for whom standard therapy has proven to be ineffective or
             intolerable, or is considered inappropriate; or for whom a clinical trial of an
             investigational agent is a recognized standard of care

          -  Participants with confirmed availability of representative tumor specimens in
             formalin-fixed, paraffin-embedded (FFPE) blocks (preferred), or sectioned tissue

          -  Participants with measurable disease per RECIST v1.1

        Additional Inclusion Criteria for Participants Who Backfill Cleared Cohorts of Phase 1a and
        Phase 1b:

          -  Backfill cohort enrollment may be limited to participants whose tumors have PD-L1
             (programmed death-ligand 1) and/or different levels of cluster of differentiation 8
             (CD8) expression, as defined by the Sponsor

          -  Backfill enrollment in Phase Ib may be managed such that approximately half of the
             patients in each backfill cohort will not have been trated with prior immune
             checkpoint inhibitors (anti-PD-L1/PD-1 [programmed death-1] and/or cytotoxic
             T-lymphocyte-associated protein 4 [CTLA-4]), except for those patients with tumor
             indications where cancer immunotherapy (CIT) is approved as treatment by local
             regulatory authorities

        Additional Inclusion Criteria for Participants in Each Indication-Specific
        Exploration/Expansion Cohort of Phase 1b:

          -  NSCLC Cohorts (CIT-Naïve): Participants with histologically confirmed incurable,
             advanced NSCLC not previously treated with anti-PD−L1/PD-1 and/or with anti-CTLA−4
             (investigational or approved), for whom a clinical trial of an investigational agent
             in combination with an anti-PD−L1/PD-1 antibody is considered an acceptable treatment
             option (if CIT [including anti-PD−L1/PD-1 agents] is approved as treatment for NSCLC
             by local regulatory authorities).

          -  NSCLC Cohort (CIT-Treated): Participants with histologically confirmed incurable,
             advanced NSCLC previously treated with anti-PD-L1/PD-1 with or without anti-CTLA-4
             (investigational or approved)

          -  Triple negative breast cancer (TNBC) Cohort: Participants with histologically
             confirmed incurable, advanced estrogen receptor (ER)-negative, progesterone
             receptor-negative, and human epidermal growth factor receptor 2 (HER2)-negative
             adenocarcinoma of the breast (triple-negative) not previously treated with
             anti-PD-L1/PD-1 and/or anti-CTLA-4 (investigational or approved)

          -  Colorectal cancer (CRC) Cohort: Participants with histologically confirmed incurable,
             advanced adenocarcinoma of the colon or rectum not previously treated with
             anti-PD-L1/PD-1 and/or anti-CTLA-4 (investigational or approved)

          -  Head and neck squamous cell carcinoma (HNSCC) Cohort: Participants with histologically
             confirmed inoperable, locally advanced or metastatic, recurrent, or persistent HNSCC
             (oral cavity, oropharynx, hypopharnyx, or larynx) not amenable to curative therapy not
             previously treated with anti-PD-L1/PD-1 and/or anti-CTLA-4 (investigational or
             approved)

          -  Urothelial carcinoma (UC) Cohort (CIT-Naïve): Participants with histologically
             confirmed incurable, advanced transitional cell carcinoma of the urothelium including
             renal pelvis, ureters, urinary bladder, and urethra, not previously treated with
             anti-PD-L1/PD-1 with or without anti-CTLA-4 (investigational or approved), for whom a
             clinical trial of an investigational agent in combination with an anti-PD−L1 antibody
             is considered an acceptable treatment option, if CIT (including anti-PD−L1/PD-1
             agents) is approved as treatment for UC by local regulatory authorities

          -  UC Cohort (CIT-Treated): Participants with histologically confirmed incurable advanced
             transitional cell carcinoma of the urothelium (including renal pelvis, ureters,
             urinary bladder, and urethra) previously treated with anti-PD-L1/PD-1 with or without
             anti-CTLA-4 (investigational or approved)

          -  Renal cell carcinoma (RCC) Cohort: Participants with histologically confirmed
             incurable, advanced RCC with component of clear cell histology and/or component of
             sarcomatoid histology not previously treated with anti-PD-L1/PD-1 and/or anti-CTLA-4
             (investigational or approved)

          -  Melanoma Cohort: Participants with histologically confirmed incurable, advanced
             melanoma not previously treated with anti-PD-L1/PD-1 and/or anti-CTLA-4
             (investigational or approved) in the metastatic setting

        Additional Inclusion Criteria for Participants in the Serial-Biopsy Expansion Cohort of
        Phase 1b:

          -  Participants must have one of the following tumor types: NSCLC, UC, HNSCC, TNBC, RCC,
             melanoma, cervical cancer, anal cancer, Merkel-cell carcinoma, microsatellite
             instability (MSI)-High tumors, squamous cell carcinoma of the skin, hepatocellular
             carcinoma (non-viral), and CRC including microsatellite stable (MSS) and MSI-Low

          -  Participants must have accessible lesion(s) that permit a total of two to three
             biopsies (pretreatment and on-treatment) or one biopsy (on-treatment, if archival
             tissue can be submitted in place of a pre-treatment biopsy) without unacceptable risk
             of a significant procedural complication. RECIST lesions should not be biopsied.

        Exclusion Criteria:

          -  Known clinically significant liver disease, including active viral, alcoholic, or
             other hepatitis, cirrhosis, and inherited liver disease or current alcohol abuse

          -  Major surgical procedure within 28 days prior to Cycle 1, Day 1, or anticipation of
             need for a major surgical procedure during the course of the study

          -  Any other diseases, metabolic dysfunction, physical examination finding, and/or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that may affect the
             interpretation of the results or may render the participant at high risk from
             treatment complications

          -  Previous splenectomy

          -  Known primary immunodeficiencies, either cellular (e.g., DiGeorge syndrome, T-negative
             severe combined immunodeficiency [SCID]) or combined T- and B-cell immunodeficiencies
             (e.g., T- and B-negative SCID, Wiskott Aldrich syndrome, ataxia telangiectasia, common
             variable immunodeficiency)

          -  Any medical condition or abnormality in clinical laboratory tests that, in the
             investigator's judgment, precludes the participant's safe participation in and
             completion of the study Cancer-Specific Exclusion Criteria

          -  Any anti-cancer therapy, whether investigational or approved, including chemotherapy,
             hormonal therapy, and/or radiotherapy, within 3 weeks prior to initiation of study
             treatment, with the exceptions as mentioned in the protocol

          -  Eligibility based on prior treatment with CIT depends on the mechanistic class of the
             drug and the cohort for which the participant is being considered, as described below.
             In addition, all criteria pertaining to adverse events attributed to prior cancer
             therapies must be met

        All Cohorts (Dose-Escalation in Phase 1a and Dose-Escalation, Backfill, and Expansion in
        Phase 1b):

          -  Prior cancer vaccines are not allowed, with the exception as specified in protocol

          -  Prior treatment with cytokines is allowed provided that at least 6 weeks or 5
             half-lives of the drug, whichever is shorter, have elapsed between the last dose and
             the proposed Cycle 1, Day 1

          -  Prior treatment with immune checkpoint inhibitors, immunomodulatory monoclonal
             antibody (mAbs), and/or mAb-derived therapies is allowed provided that at least 6
             weeks (Phase 1a) or 3 weeks (Phase 1b) have elapsed between the last dose and the
             proposed Cycle 1, Day 1, with the exceptions as specified in protocol

        Dose-Exploration/Expansion Cohorts in Phase 1b:

          -  In the NSCLC CIT-Treated exploration cohort in Phase 1b, the most recent systemic
             treatment should have been anti-PD−L1/PD-1 and/or anti-CTLA-4 as monotherapy or in
             combination

          -  In the NSCLC CIT-Naïve expansion cohort in Phase 1b, prior treatment with
             anti-PD−L1/PD-1 and/or anti-CTLA-4 (investigational or approved) is not allowed

          -  Prior treatment with immunomodulators, including toll-like receptor (TLR) agonists,
             inhibitors of indoleamine 2,3-dioxygenase (IDO)/ tryptophan-2,3-dioxygenase (TDO), or
             agonists of OX40, is allowed provided that at least 5 half-lives of the drug or a
             minimum of 3 weeks have elapsed between the last dose of the prior treatment and the
             proposed Cycle 1, Day 1, with the exception as specified in protocol

          -  Any history of an immune-related Grade 4 adverse event attributed to prior CIT (other
             than endocrinopathy managed with replacement therapy or asymptomatic elevation of
             serum amylase or lipase)

          -  Any history of an immune-related Grade 3 adverse event attributed to prior CIT (other
             than hypothyroidism managed with replacement therapy) that resulted in permanent
             discontinuation of the prior immunotherapeutic agent and/or occurred less than or
             equal to (&lt;=) 6 months prior to Cycle 1 Day 1

          -  Adverse events from prior anti-cancer therapy that have not resolved to Grade &lt;=1
             except for alopecia, vitiligo, or endocrinopathy managed with replacement therapy

          -  All immune-related adverse events related to prior CIT (other than endocrinopathy
             managed with replacement therapy or stable vitiligo) must have resolved completely to
             baseline

          -  Primary central nervous system (CNS) malignancy, untreated CNS metastases, or active
             CNS metastases (progressing or requiring corticosteroids for symptomatic control)

          -  Leptomeningeal disease

          -  Uncontrolled tumor-related pain

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
             drainage procedures

          -  Malignancies other than disease under study within 5 years prior to Cycle 1, Day 1,
             with the exception of those with a negligible risk of metastasis or death

          -  Uncontrolled hypercalcemia

          -  Participant has spinal cord compression not definitively treated with surgery and/or
             radiation or previously diagnosed and treated spinal cord compression without evidence
             that disease has been clinically stable for &gt;=2 weeks prior to screening

        Treatment-Specific Exclusion Criteria:

          -  History of autoimmune disease with caveats as specified in protocol

          -  Treatment with systemic immunosuppressive medications within 2 weeks prior to Cycle 1,
             Day 1

          -  History of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia, or
             evidence of active pneumonitis on screening chest computed tomography (CT) scan

          -  Positive test for human immunodeficiency virus (HIV) infection

          -  Active hepatitis B, hepatitis C

          -  Known active or latent tuberculosis infection

          -  Severe infections within 4 weeks prior to Cycle 1, Day 1

          -  Recent infections not meeting the criteria for severe infections within 2 weeks prior
             to Cycle 1, Day 1

          -  Prior allogeneic bone marrow transplantation or prior solid organ transplantation

          -  Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or
             anticipation that such a live attenuated vaccine will be required during the study

          -  Known hypersensitivity to the active substance or to any of the excipients in the
             vaccine

          -  Phase 1b and crossover only: History of severe allergic, anaphylactic, or other
             hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins;
             Known hypersensitivity to Chinese Hamster Ovary (CHO)-cell products; Allergy or
             hypersensitivity to components of the atezolizumab formulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO39733 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Research Institute - Pima Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Angeles Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5820</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-2517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University Cancer Center, Smilow Cancer Hospital; Medical Oncology</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Can Ins</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center; Clinical Research Management Office</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Oncology and Hematology Care Eastside</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Res Inst; TN Onc</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Sart-Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sint Augustinus Wilrijk</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre; Oncology</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center; Department of Radiation Oncology</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>LungenClinic Großhansdorf</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nationales Centrum für Tumorerkrankungen Heidelberg (NCT); Thoraxklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fachklinik für Lungenerkrankungen</name>
      <address>
        <city>Immenhausen</city>
        <zip>34376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>2300 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra; Servicio de oncología</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska Hospital; Oncology - Radiumhemmet</name>
      <address>
        <city>Solna</city>
        <zip>171 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset, Onkologkliniken</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barts &amp; London School of Med; Medical Oncology</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital; Medical Oncology</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2017</study_first_submitted>
  <study_first_submitted_qc>September 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2017</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer vaccine</keyword>
  <keyword>Neoantigen</keyword>
  <keyword>Personalized</keyword>
  <keyword>Atezolizumab</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Anti-PDL1</keyword>
  <keyword>Checkpoint Inhibitor</keyword>
  <keyword>Personalized vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

